0.4173

4.55% -0.0199

After Hours: .44 0.0227 +5.44%

Lineage Cell Therapeutics Inc (LCTX)

Overview News Price History Option Chain Discussions Forecast Stock Split

Lineage Cell Therapeutics Inc stock is traded at $0.4173, with a volume of 1.14M. It is down -4.55% in the last 24 hours and down -18.19% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.

Previous Close:

$0.4372

Open:

$0.409

24h Volume:

1.14M

Relative Volume:

0.69

Market Cap:

$95.29M

Revenue:

$8.95M

Net Income/Loss:

$-21.49M

P/E Ratio:

-3.4775

EPS:

-0.12

Net Cash Flow:

$-29.24M

1W Performance:

-15.97%

1M Performance:

-18.19%

6M Performance:

-53.58%

1Y Performance:

-69.32%

1-Day Range:

$0.409

$0.4213

1-Week Range:

$0.4011

$0.499

52-Week Range:

$0.4011

$1.56

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name

Lineage Cell Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (678)

Phone

510-871-4188

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA

Employee

Twitter

@LineageCell

Next Earnings Date

2025-03-10

Latest SEC Filings

LCTX's Discussions on Twitter

Compare LCTX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LCTX Lineage Cell Therapeutics Inc	0.4173	95.29M	8.95M	-21.49M	-29.24M	-0.12
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	68.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-20-24	Initiated	Craig Hallum	Buy
Nov-02-22	Initiated	Robert W. Baird	Outperform
Jun-14-22	Initiated	B. Riley Securities	Buy
Aug-19-21	Initiated	Noble Capital Markets	Outperform
Mar-31-21	Initiated	Cantor Fitzgerald	Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

Apr 02, 2025

LCTX Stock: A Comprehensive Analysis and Forecast - investchronicle.com

Apr 02, 2025

Mar 27, 2025

LCTX stock touches 52-week low at $0.48 amid market challenges - Investing.com

Mar 27, 2025

Lineage Cell Therapeutics : Wave Life Sciences Announces Positive Data from FORWARD 53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE N531 - MarketScreener

Mar 27, 2025

Mar 25, 2025

Cell Therapy Manufacturing Market Demand, Growth and Future - openPR.com

Mar 25, 2025

Mar 18, 2025

LCTX stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa

Mar 18, 2025

Mar 17, 2025

B. Riley Forecasts Lineage Cell Therapeutics Q1 Earnings - Defense World

Mar 17, 2025

Mar 16, 2025

B. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World

Mar 16, 2025

Mar 15, 2025

Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress - TipRanks

Mar 15, 2025

Mar 14, 2025

B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating - Marketscreener.com

Mar 14, 2025

HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings - Defense World

Mar 14, 2025

Mar 13, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World

Mar 13, 2025

Mar 12, 2025

Cell Therapy Manufacturing Market Poised for Expansion Biotech - openPR

Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail

Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, - openPR

Mar 12, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 12, 2025

Lineage Cell Therapeutics stock target cut to $3 by Craig-Hallum - Investing.com Australia

Mar 12, 2025

Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies - TipRanks

Mar 12, 2025

Mar 11, 2025

Lineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Mar 11, 2025

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 11, 2025

Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock - Benzinga

Mar 11, 2025